Novartis India Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Vas Narasimhan

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.5yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Vas Narasimhan (48 yo)

6.8yrs

Görev süresi

Dr. Vasant Narasimhan, also known as Vas, M.D., serves as Chief Executive Officer of Novartis AG at Novartis India Ltd. Dr. Narasimhan has been Chief Executive Officer of Novartis AG since February 1, 2018...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shilpa Joshi	CFO & Whole-Time Director	2.5yrs	Veri yok	Veri yok
Chandni Maru	Company Secretary & Compliance Officer	less than a year	Veri yok	Veri yok
Falin Majmudar	Whole–Time Director	less than a year	Veri yok	Veri yok
Vasant Narasimhan	Chief Executive Officer of Novartis	6.8yrs	Veri yok	Veri yok

1.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 500672 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shilpa Joshi	CFO & Whole-Time Director	2yrs	Veri yok	Veri yok
Falin Majmudar	Whole–Time Director	less than a year	Veri yok	Veri yok
Sanker Parameswaran	Independent Non-Executive Director	4.4yrs	₹1.00m	Veri yok
Christopher Snook	Non-Executive Chairman	16.3yrs	Veri yok	Veri yok
Sandra Martyres	Independent Non-Executive Director	8.6yrs	₹1.00m	Veri yok
Gira Sardesai	Independent Director	less than a year	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 500672 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Novartis India Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Novartis India Limited, Annual General Meeting, Jul 31, 2024

Novartis India Limited Announces Appointment of Chandni Maru as Company Secretary and Compliance Officer

Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024

Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024

Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024

Insufficient new directors

Recent updates

Second quarter 2025 earnings released: EPS: ₹8.27 (vs ₹9.59 in 2Q 2024)

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis India Limited to Report First Half, 2025 Results on Oct 25, 2024

Now 20% overvalued after recent price rise

Upcoming dividend of ₹25.00 per share

Full year 2024 earnings released: EPS: ₹34.50 (vs ₹41.86 in FY 2023)

Novartis India Limited to Report Q1, 2025 Results on Jul 29, 2024

Dividend of ₹25.00 announced

Full year 2024 earnings released: EPS: ₹34.50 (vs ₹41.86 in FY 2023)

Novartis India Limited, Annual General Meeting, Jul 31, 2024

Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 5, 2024

Novartis India Limited Announces Appointment of Chandni Maru as Company Secretary and Compliance Officer

Novartis India Limited to Report Fiscal Year 2024 Results on May 10, 2024

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024

Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024

Novartis India Limited to Report Q3, 2024 Results on Jan 25, 2024

First quarter 2024 earnings released: EPS: ₹8.21 (vs ₹21.21 in 1Q 2023)

Upcoming dividend of ₹47.50 per share at 1.2% yield

Insufficient new directors

Novartis India Limited Proposes One-Time Special Dividend

Full year 2023 earnings released: EPS: ₹41.86 (vs ₹1.51 loss in FY 2022)

Novartis India Limited, Annual General Meeting, Jul 28, 2023

Third quarter 2023 earnings released: EPS: ₹3.08 (vs ₹2.57 in 3Q 2022)

Novartis India Limited to Report Q3, 2023 Results on Feb 08, 2023

Novartis India Limited Announces Resignation of Monaz Noble as Non-Executive and Non-Independent Director, Effective November 21, 2022

Novartis India Limited to Report Q2, 2023 Results on Nov 09, 2022

Upcoming dividend of ₹10.00 per share

Novartis India Limited to Report Q1, 2023 Results on Jul 27, 2022

Full year 2022 earnings released: ₹1.51 loss per share (vs ₹8.47 profit in FY 2021)

Novartis India Limited, Annual General Meeting, Jul 29, 2022

Novartis India Limited Appoints Nikhil Malpani as Company Secretary and Key Managerial Personnel

Novartis India Limited to Report Q4, 2022 Results on May 19, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Company Secretary & Compliance Officer Trivikram Guda has left the company

Second quarter 2022 earnings released: EPS ₹2.84 (vs ₹3.05 in 2Q 2021)

Upcoming dividend of ₹10.00 per share

Full year 2021 earnings released: EPS ₹8.47 (vs ₹4.08 in FY 2020)

Full year 2021 earnings released: EPS ₹8.46 (vs ₹4.08 in FY 2020)

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

Third quarter 2021 earnings released: ₹0.29 loss per share (vs ₹3.13 profit in 3Q 2020)

New 90-day high: ₹694

Second quarter 2021 earnings released: EPS ₹3.05

New 90-day high: ₹678

Novartis India Limited to Report Q2, 2021 Results on Nov 05, 2020

First quarter earnings released

Upcoming Dividend of ₹10.00 Per Share

Novartis India Limited to Report Q1, 2021 Results on Aug 06, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş